<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46539">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500381</url>
  </required_header>
  <id_info>
    <org_study_id>4045-301</org_study_id>
    <nct_id>NCT02500381</nct_id>
  </id_info>
  <brief_title>Study of SRP-4045 and SRP-4053 in DMD Patients</brief_title>
  <acronym>ESSENCE</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053
      compared to placebo in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion
      mutations amenable to skipping exon 45 and exon 53 respectively. Additional objectives
      include evaluation of safety, pharmacokinetics and biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, multi-center study to evaluate the efficacy and
      safety of SRP-4045 and SRP-4053. Eligible patients with out-of-frame deletion mutations
      amenable to exon 45 or 53 skipping will be randomized to receive once weekly intravenous
      (IV) infusions of 30 mg/kg SRP-4045 or 30 mg/kg SRP-4053 respectively (combined-active
      group, 66 patients) or placebo (33 patients) for up to 96 weeks (the placebo-controlled
      period of the trial). This will be followed by an open label extension period in which all
      patients will receive open-label active treatment for up to 96 weeks.

      The study will enroll approximately 99 patients, with a planned minimum target of 45
      patients amenable to exon 45 skipping and 45 patients amenable to exon 53 skipping.

      Approximately 66 patients will be randomized to receive active treatment with either
      SRP-4045 or SRP-4053 (depending on deletion mutation), and 33 patients will be randomized to
      receive placebo. Twice as many patients will receive active treatment as will receive
      placebo (2:1 randomization).

      When approximately 75 patients have been in the trial for 48 weeks a group of independent
      experts will review key study results and will make a determination on whether patients will
      roll into the open-label period of the study and receive active drug or continue in the
      placebo-controlled period out to Week 96 as planned.

      Clinical efficacy will be assessed at regularly scheduled study visits, including functional
      tests such as the six-minute walk test (6MWT). All patients will undergo a muscle biopsy at
      baseline and a second muscle biopsy at Week 48.

      Safety will be assessed through the collection of adverse events (AEs), laboratory tests,
      electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations
      throughout the study.

      Blood samples will be taken periodically throughout the study to assess the pharmacokinetics
      of both drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6 Minute Walk Test (6MWT) from Baseline</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dystrophin protein expression</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to rise independently from the floor</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status as measured by loss of ambulation (LOA) from Baseline</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North Star Ambulatory Assessment (NSAA) from Baseline</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC)% predicted from Baseline</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of falls from Baseline</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) from baseline</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>DMD</condition>
  <condition>Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>SRP-4045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A planned minimum of 33 DMD patients with deletion mutations amenable to exon 45 skipping will be randomized to the active SRP-4045 group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRP-4053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A planned minimum of 33 DMD patients with deletion mutations amenable to exon 53 skipping will be randomized to the active SRP-4053 group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 33 DMD patients with deletion mutations amenable to exon 45 or exon 53 skipping will be randomized to the placebo group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4045</intervention_name>
    <description>SRP-4045 30 mg/kg will be administered as an IV infusion once a week for up to 96 weeks.
In the Open-Label Period, all patients will receive IV infusions of SRP-4045 at 30 mg/kg/week for up to 96 weeks.</description>
    <arm_group_label>SRP-4045</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4053</intervention_name>
    <description>SRP-4053 30 mg/kg will be administered as an IV infusion once a week for up to 96 weeks.
In the Open-Label Period, all patients will receive IV infusions of SRP-4053 at 30 mg/kg/week for up to 96 weeks.</description>
    <arm_group_label>SRP-4053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as an IV infusion once a week for up to 96 weeks.
In the Open-Label Period, all patients will receive IV infusions of either SRP-4045 or SRP-4053 at 30 mg/kg/week, according to genotype, for up to 96 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 7-13 years old

          -  Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53
             skipping

          -  Stable dose of corticosteroids for at least 6 months

          -  Intact right and left biceps or 2 alternative upper muscle groups

          -  Mean 6MWT greater than or equal 300 meters and less than or equal to 450 meters

          -  Stable pulmonary and cardiac function: forced vital capacity (FVC) equal to or
             greater than 50% predicted and left ventricular ejection fraction (LVEF) greater than
             50%

        Exclusion Criteria:

          -  Previous treatment with the following experimental compounds: SMT C1100 (BMN-195) at
             any time

          -  Previous treatment with PRO045 or PRO053 within 6 months prior to Week 1

          -  Current or previous treatment with any other experimental treatment (other than
             deflazacort) within 12 weeks prior to Week 1

          -  Participation in any other DMD interventional clinical study within 12 weeks prior to
             Week 1

          -  Major surgery within 3 months prior to Week 1

          -  Presence of other clinically significant illness

          -  Major change in physical therapy regimen within 3 months prior to Week 1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genevieve Laforet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward M Kaye, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Boniface</last_name>
    <email>trialinfo@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuscular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Osgood</last_name>
      <phone>480-314-1007</phone>
      <email>kosgood@nrcaz.com</email>
    </contact>
    <investigator>
      <last_name>Kumaraswamy Sivakumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Dozal</last_name>
      <phone>323-361-5825</phone>
      <email>cdozal@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Leigh Maria Ramos-Platt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bonitati</last_name>
      <phone>310-825-3264</phone>
      <email>MBonitati@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine/Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Mclaughlin</last_name>
      <phone>650-206-3178</phone>
      <email>cjmclaug@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NW Florida Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shae Lancelin</last_name>
      <email>shae.lancelin@cneurology.com</email>
    </contact>
    <investigator>
      <last_name>Ben Renfroe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Oswald</last_name>
      <phone>312-227-4483</phone>
      <email>TOswald@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Kuntz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Stephan</last_name>
      <phone>319-356-2673</phone>
      <email>carrie-stephan@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas, Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiley Sims</last_name>
      <email>ksims2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffery Statland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Christenson</last_name>
      <phone>314-362-6991</phone>
      <email>christensont@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ann M Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn McKenna</last_name>
      <phone>702-505-4230</phone>
      <email>mckenna.k@lasvegasclinic.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan McKinnon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Clinical Research Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Smith</last_name>
      <phone>585-275-4339</phone>
      <email>Patty_Smith@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Emma Ciafaloni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center (CCHMC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Collins</last_name>
      <phone>513-636-5517</phone>
      <email>andrea.collins@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>John Jefferies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Moffitt</last_name>
      <phone>614-722-8528</phone>
      <email>lisa.moffitt@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jerry R Mendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M Monahan</last_name>
      <phone>412-692-5176</phone>
      <email>jennifer.monahan@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Hoda Z Abdel-Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>TBD</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>TBD</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinal Patel</last_name>
      <phone>020 7905 2639</phone>
      <phone_ext>2639</phone_ext>
      <email>hinal.patel@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Francesco Muntoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>July 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
